Nature magazine article on compound acquisition
Buying cheap can be very expensive in the end
Compound acquisition:
„Buying cheap can be very expensive in the end“, says Dimitrios Tzalis, CEO of Taros Chemicals and Chemistry Leader of the EU Lead Factory in Nature magazine 548, 485–488, doi:10.1038/548485a.
Read the full article – “check your chemistry”
About Taros Chemicals
Taros is a privately owned discovery chemistry company, working with global pharmaceutical, biotech and chemical companies since 1999. Alongside our performance chemicals and material science division, Taros’ drug discovery mission is to create drug candidates as potential new medicines. Taros has a strong scientific track record on many biomolecular targets in all main therapeutic areas and thereby adding considerable value to collaborations from target validation and hit identification to lead generation and optimization. Taros’ core expertise ranges from custom synthesis and process development to modern medicinal and computational chemistry, as well as compound library design and production.
Taros was heading the chemistry efforts of the EUR 196 million funded European Lead Factory (2013-2018) and is currently heading its EUR 36.5 million funded continuation (2019-2022). Moreover, Taros is deeply engaged in other research alliances like the EUR 11 million funded Drug Discovery Hub Dortmund.
Press Contact:
Youri R. Mesmoudi, Executive Vice President, e-mail: innovation |at| taros.de
Drug Discovery
Taros’ international and multidisciplinary team has more than 180 years of pharmaceutical R&D experience. Collectively as a team, we worked on more than 120 biomolecular…
Material Science
We create performance chemicals to enhance new materials, plastics, coatings, dyes & inks, cosmetics, flavors and many more research and industrial applications…
